Pages

Thursday, July 24, 2014

Merck Initiates Phase 3 Study of Letermovir, an Investigational...

Merck , known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir , an investigational antiviral agent.

http://ift.tt/1nXjQ7k

No comments:

Post a Comment